IDEXX Laboratories, Inc. (IDXX)
What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now?
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Idexx Laboratories (IDXX) Just Flashed Golden Cross Signal: Do You Buy?
Idexx Laboratories (IDXX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IDXX broke through the 20-day moving average, which suggests a short-term bullish trend.
Idexx Laboratories (IDXX) Just Overtook the 50-Day Moving Average
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
IDEXX Laboratories: A Strong Third Quarter With Good Future Prospects
IDEXX Laboratories (IDXX) continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, alongside expanding margins and reduced debt. International growth, new product launches like InVueDx, and ongoing share buybacks are key catalysts for future performance.
IDEXX Laboratories Jumps 15% on Q3 Earnings Beat
IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance.
IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. ( IDXX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jay Mazelsky - President, CEO & Director Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Michael Ryskin - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Keith Devas - Jefferies LLC, Research Division Presentation Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2025 Earnings Conference Call.
Idexx Stock Pops on Earnings. Pet Health Is Booming.
Vet visits are down, but growing revenue per visit is more than making up for it, the company says.
Countdown to Idexx (IDXX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
